<DOC>
	<DOCNO>NCT01734252</DOCNO>
	<brief_summary>Critically ill patient high risk thrombosis tromboembolic event presence heparin resistance , treat Department General Surgical Critical Care Medicine Medical University Innsbruck , Austria enrol study meeting inclusion- exclusion criterion . If patient meet inclusion criterion recruit study , patient randomize either Group A Group H. All patient achieve prophylactic aPTT-target range aPTT-level 45 - 60 sec ( Pathromtin® SL ) within 6 8 hour . Randomisation Group A : If Heparin resistance appear patient meet inclusion exclu-sion criterion , he/she enrol . The Heparin administration stop Argatroban give adjust target aPTT-range achieve . Randomisation Group H - Standard therapy : If Heparin resistance appear patient meet inclusion exclu-sion criterion , he/she enrol . The Heparin administration contin-ued , necessary increase . Hereby maximum heparin dose 1.500 IU per hour . Therapy failure Group H : Primary target failure Visit 3 ( 6-8 hour ) : If patient Group H achieve target-aPTT within 6-8 hour , he/she switch Group A start T1 ( Baseline ) follow visit accord Group A final Visit 9 ( T1 / day 30 ) . Maintenance failure Visit 3 : Maintenance failure 6-8 hour define non-maintenance tar-get-aPTT day 7 max . heparin dosage 1.500 IU per hour . In case , heparin therapy change Argatroban . The patient start T1 ( Baseline ) follow visit accord Group A final Visit 9 ( day 30 ) count Baseline Group A . Therapy failure Group A : If patient Group A achieve target-aPTT within 6-8 hour maintain target-aPTT spite reach maximum dosage 10µg/kg/min study period , patient automatically drop study . The effective patient switch Group A therapy failure Group H. General : Two hour start Baseline investigation , patient 's parameter in-cluding blood collection measure second time ( T2 ) . Additional measurement make 6-8 hour ( T3 ) , 24 hour ( T4 ) , 48 hour ( T5 ) , 5 day ( T6 ) start study drug day 7 ( T7 ) stop study medication 6h ( T8 ) stop study medication . 30 day inclusion study , final investigation plan ( T9 ) .</brief_summary>
	<brief_title>Argatroban Critically Ill Patients With Heparin Resistance</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Argatroban</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Patient risk thrombosis thromboembolic complication need prophylactic antithrombotic therapy Age : 18 85 year Prohylactic anticoagulation ( aPTT : 45 60 sec ) achieve heparin dosage 1.200 IU per hour two hour infusion If patient need aPTTlevel &gt; 60 sec reason Active bleeding Risk bleed high risk thromboembolic event anticipate physician Surgical procedure need interruption antithrombotic therapy within next 24 hour Inevitable lethal course Severe Liver failure : Quick &lt; 30 % Pregnancy Planned peridural spinal anaesthesia study Patient know refusal participation clinical trial Active participation another clinical trial Any condition , include presence laboratory abnormality , would place subject unacceptable risk he/she participate study confound ability interpret data study Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>